Cemtrex (NASDAQ: CETX, CETXP, CETXW), a world lead
Post# of 102250
![Avatar](/images/ProfileImages/no_avatar_available.jpg)
Fiscal Year 2017 Highlights:
Revenue increased by 29% to $120,628,200 for the twelve months ended in September 30, 2017 compared to $93,704,560 for the same period in 2016.
Comprehensive Income to Common shareholders was even at $4,029,699 for fiscal year ended September 30, 2017 as compared to $4,019,898 for fiscal year ended September 30, 2016.
Earnings Per Share for 2017 was $.31 compared to $.58 for 2016, a decrease of 32%. The Company paid Preferred stock dividend of $1,200,871 during fiscal year ended September 30, 2017 as compared to $0.00 for fiscal year ended September 30, 2016. The Company had 10,175,736 common shares outstanding at the end of fiscal 2017 as compared to 8,514,772 shares outstanding at the end of fiscal 2016 on a diluted basis.
EBITDA was down 5.3% to $8,571,125 in the twelve month period ended September 30, 2017 compared to EBITDA of $9,053,839 in the same period in 2016.
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)
1️⃣I do not provide personal investment advice and I am not a qualified licensed investment advisor. I am an amateur investor.
2️⃣All information found here, including any ideas, opinions, views, predictions, forecasts, commentaries, suggestions, or stock picks, expressed or implied herein, are for informational, entertainment or educational purposes only and should not be construed as personal investment advice. While the information provided is believed to be accurate, it may include errors or inaccuracies.
3️⃣I will not and cannot be held liable for any actions you take as a result of anything you read here.
4️⃣Conduct your own due diligence, or consult a licensed financial advisor or broker before making any and all investment decisions. Any investments, trades, speculations, or decisions made on the basis of any information found on this site, expressed or implied herein, are committed at your own risk, financial or otherwise.